Cited by 231Genomics and Rare DiseasesConnective tissue disorders researchMetabolism and Genetic Disorders

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Lessons learned from additional research analyses of unsolved clinical exome cases

Open access

Abstract

BACKGROUND: Given the rarity of most single-gene Mendelian disorders, concerted efforts of data exchange between clinical and scientific communities are critical to optimize molecular diagnosis and novel disease gene discovery. METHODS: We designed and implemented protocols for the study of cases for which a plausible molecular diagnosis was not achieved in a clinical genomics diagnostic laboratory (i.e. unsolved clinical exomes). Such cases were recruited to a research laboratory for further analyses, in order to potentially: (1) accelerate novel disease gene discovery; (2) increase the molecular diagnostic yield of whole exome sequencing (WES); and (3) gain insight into the genetic mechanisms of disease. Pilot project data included 74 families, consisting mostly of parent-offspring trios. Analyses performed on a research basis employed both WES from additional family members and complementary bioinformatics approaches and protocols. RESULTS: Analysis of all possible modes of Mendelian inheritance, focusing on both single nucleotide variants (SNV) and copy number variant (CNV) alleles, yielded a likely contributory variant in 36% (27/74) of cases. If one includes candidate genes with variants identified within a single family, a potential contributory variant was identified in a total of ~51% (38/74) of cases enrolled in this pilot study. The molecular diagnosis was achieved in 30/63 trios (47.6%). Besides this, the analysis workflow yielded evidence for pathogenic variants in disease-associated genes in 4/6 singleton cases (66.6%), 1/1 multiplex family involving three affected siblings, and 3/4 (75%) quartet families. Both the analytical pipeline and the collaborative efforts between the diagnostic and research laboratories provided insights that allowed recent disease gene discoveries (PURA, TANGO2, EMC1, GNB5, ATAD3A, and MIPEP) and increased the number of novel genes, defined in this study as genes identified in more than one family (DHX30 and EBF3). CONCLUSION: An efficient genomics pipeline in which clinical sequencing in a diagnostic laboratory is followed by the detailed reanalysis of unsolved cases in a research environment, supplemented with WES data from additional family members, and subject to adjuvant bioinformatics analyses including relaxed variant filtering parameters in informatics pipelines, can enhance the molecular diagnostic yield and provide mechanistic insights into Mendelian disorders. Implementing these approaches requires collaborative clinical molecular diagnostic and research efforts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-017-0412-6

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Analysis of WES data. a SNVs were filtered and prioritized according to specific criteria, including mode of inheritance, mutation type, variant frequency, conservation, and predictions of pathogenicity. b Candidate genes were further prioritized by data mining, taking into consideration gene function, expression, and networks. In addition, other cohorts were interrogated for additional families with variants in the same candidate gene. MutationMapper (http://www.cbioportal.org/mutation_mapper.jsp), ARIC Atherosclerosis Risk in Communities Study, AR-Hom autosomal recessive-homozygous, BHCMG Baylor-Hopkins Center for Mendelian Genomics, BG Baylor Genetics laboratories, CNV copy number variation, Comp compound, db database, ExAC Exome Aggregation Consortium, Het heterozygous, HGMD Human Gene Mutation Database, MAF minor allele frequency; SNV single nucleotide variant, XLR-Hem X-linked recessive-hemizygous
Fig. 1 Analysis of WES data. a SNVs were filtered and prioritized according to specific criteria, including mode of inheritance, mutation type, variant frequency, conservation, and predictions of pathogenicity. b Candidate genes were further prioritized by data mining, taking into consideration gene function, expression, and networks. In addition, other cohorts were interrogated for additional families with variants in the same candidate gene. MutationMapper (http://www.cbioportal.org/mutation_mapper.jsp), ARIC Atherosclerosis Risk in Communities Study, AR-Hom autosomal recessive-homozygous, BHCMG Baylor-Hopkins Center for Mendelian Genomics, BG Baylor Genetics laboratories, CNV copy number variation, Comp compound, db database, ExAC Exome Aggregation Consortium, Het heterozygous, HGMD Human Gene Mutation Database, MAF minor allele frequency; SNV single nucleotide variant, XLR-Hem X-linked recessive-hemizygousCC BY · PubMed Central
Fig. 2 Overview of the study design and results. a Clinical WES cases that lacked a definitive molecular diagnosis (left) were eligible for recruitment into a research environment. In a pilot study of 74 families (right), we identified strong candidate genes for 51% (38/74) of cases. Identified variants were categorized into six major classes based on mode of inheritance and known or novel gene. b According to stringent criteria, a potential contributory variant was achieved in 27 of 74 (36%) cases. Of these, 12 were independently solved by the clinical exome laboratory upon reanalysis of WES data and updated literature review. When taking into account strong candidate genes identified in only a single family to date, a potential molecular diagnostic rate of 51% was achieved
Fig. 2 Overview of the study design and results. a Clinical WES cases that lacked a definitive molecular diagnosis (left) were eligible for recruitment into a research environment. In a pilot study of 74 families (right), we identified strong candidate genes for 51% (38/74) of cases. Identified variants were categorized into six major classes based on mode of inheritance and known or novel gene. b According to stringent criteria, a potential contributory variant was achieved in 27 of 74 (36%) cases. Of these, 12 were independently solved by the clinical exome laboratory upon reanalysis of WES data and updated literature review. When taking into account strong candidate genes identified in only a single family to date, a potential molecular diagnostic rate of 51% was achievedCC BY · PubMed Central
Fig. 3 Location of DHX30 and GNB5 variants, dinucleotide variants culled from WES data and UPD. a Variants identified in DHX30 and GNB5 are located in specific protein domains. b Sanger confirmation of a de novo dinucleotide variant in SYN3. c The B-allele frequency extracted from WES data in the patient with the homozygous SLC1A4 variant showed a single region of AOH in the genome (chromosome 2), suggestive of uniparental disomy (UPD) of chromosome 2. d Segregation analysis of the SLC1A4 homozygous variant did not conform to Mendelian expectations
Fig. 3 Location of DHX30 and GNB5 variants, dinucleotide variants culled from WES data and UPD. a Variants identified in DHX30 and GNB5 are located in specific protein domains. b Sanger confirmation of a de novo dinucleotide variant in SYN3. c The B-allele frequency extracted from WES data in the patient with the homozygous SLC1A4 variant showed a single region of AOH in the genome (chromosome 2), suggestive of uniparental disomy (UPD) of chromosome 2. d Segregation analysis of the SLC1A4 homozygous variant did not conform to Mendelian expectationsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Cited by

Sorted by citations

Metadata

Authors
Eldomery, M. K., Coban-Akdemir, Z., Harel, T., Rosenfeld, J. A., Gambin, T., Stray-Pedersen, A., Küry, S., Mercier, S., Lessel, D., Denecke, J., Wiszniewski, W., Penney, S., Liu, P., Bi, W., Lalani, S. R., Schaaf, C. P., Wangler, M. F., Bacino, C. A., Lewis, R. A., Potocki, L., Graham, B. H., Belmont, J. W., Scaglia, F., Orange, J. S., Jhangiani, S. N., Chiang, T., Doddapaneni, H., Hu, J., Muzny, D. M., Xia, F., Beaudet, A. L., Boerwinkle, E., Eng, C. M., Plon, S. E., Sutton, V. R., Gibbs, R. A., Posey, J. E., Yang, Y., & Lupski, J. R.
Affiliations
  • Baylor College of Medicine (US)
  • Warsaw University of Technology (PL)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • University Medical Center Hamburg-Eppendorf (DE)
Corresponding author
Lupski, James R.
Venue
Genome Medicine
Published
2017-03-21
Volume
9
Issue
1
Pages
26-26
ISSN
1756-994X (ISSN-L)
OpenAlex
W2598900401
Cited by
230
References
111
Citations by year
2026: 7 · 2025: 6 · 2024: 22 · 2023: 22 · 2022: 30 · 2021: 27 · 2020: 33 · 2019: 43 · 2018: 30 · 2017: 10
FWCI
21.00
Type
journal article
Language
en
Open access
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
  • National Human Genome Research Institute (U54HG006542)
  • National Institutes of Health (T32 GM07526, NIH T32 GM07526)
  • Genetics Resource Association of Texas
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
monogenic disorders, disease gene discovery, molecular diagnosis, exome sequencing, parent-offspring trios, copy number variation, single nucleotide variants, clinical research collaboration, multiplex families, PURA, TANGO2, GNB5, ATAD3A, MIPEP, DHX30, EBF3
MeSH terms
ATPases Associated with Diverse Cellular Activities, Adenosine Triphosphatases, DNA-Binding Proteins, Female, Humans, Male, Membrane Proteins, Metalloendopeptidases, Pilot Projects, Transcription Factors, Sequence Analysis, DNA, Computational Biology, Polymorphism, Single Nucleotide, Genomics, Mitochondrial Proteins, Genetic Diseases, Inborn, GTP-Binding Protein beta Subunits, DNA Copy Number Variations, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review